Bausch + Lomb Corporation (BLCO)

USD 11.5

(-0.78%)

Operating Income Summary of Bausch + Lomb Corporation

  • Bausch + Lomb Corporation's latest annual operating income in 2023 was 130 Million USD , down -37.2% from previous year.
  • Bausch + Lomb Corporation's latest quarterly operating income in 2024 Q3 was 43 Million USD , up 7.5% from previous quarter.
  • Bausch + Lomb Corporation reported an annual operating income of 207 Million USD in 2022, down -37.08% from previous year.
  • Bausch + Lomb Corporation reported an annual operating income of 329 Million USD in 2021, up 26.54% from previous year.
  • Bausch + Lomb Corporation reported a quarterly operating income of 15 Million USD for 2024 Q1, down -69.39% from previous quarter.
  • Bausch + Lomb Corporation reported a quarterly operating income of 40 Million USD for 2024 Q2, up 166.67% from previous quarter.

Annual Operating Income Chart of Bausch + Lomb Corporation (2023 - 2018)

Historical Annual Operating Income of Bausch + Lomb Corporation (2023 - 2018)

Year Operating Income Operating Income Growth
2023 130 Million USD -37.2%
2022 207 Million USD -37.08%
2021 329 Million USD 26.54%
2020 260 Million USD -51.13%
2019 532 Million USD 27.88%
2018 416 Million USD 0.0%

Peer Operating Income Comparison of Bausch + Lomb Corporation

Name Operating Income Operating Income Difference
Alcon Inc. 1.03 Billion USD 87.488%
AptarGroup, Inc. 404.01 Million USD 67.823%
Baxter International Inc. 390 Million USD 66.667%
Becton, Dickinson and Company 2.42 Billion USD 94.639%
Haemonetics Corporation 164.88 Million USD 21.156%
Envista Holdings Corp 31.5 Million USD -312.698%
ResMed Inc. 1.31 Billion USD 90.151%
Teleflex Incorporated 506.31 Million USD 74.324%
Warby Parker Inc. -71.99 Million USD 280.566%
West Pharmaceutical Services, Inc. 676 Million USD 80.769%